Erasmus Medical Center

The new subtypes could help clinicians pick alternative therapies for patients unlikely to respond to Bacillus Calmette-Guérin treatment.

By sequencing dozens of locally advanced or metastatic neuroendocrine neoplasm samples, researchers detected somatic mutations that varied with primary tumor site and subtype.

GeneCentric and Erasmus will aim to identify RNA-based drug response markers for existing bladder cancer treatments, as well as discover novel targeted therapies.